Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008–2014
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Background. Echinocandins are first-line treatment for Candida glabrata candidemia. Echinocandin resistance is concerning due to limited remaining treatment options. We used data from a multisite, population-based surveillance program to describe the epidemiology and risk factors for echinocandin nonsusceptible (NS) C glabrata candidemia. Methods. The Centers for Disease Control and Prevention's Emerging Infections Program conducts population-based laboratory surveillance for candidemia in 4 metropolitan areas (7.9 million persons; 80 hospitals). We identified C glabrata cases occurring during 2008–2014; medical records of cases were reviewed, and C glabrata isolates underwent broth microdilution antifungal susceptibility testing. We defined echinocandin-NS C glabrata (intermediate or resistant) based on 2012 Clinical and Laboratory Standards Institute minimum inhibitory concentration breakpoints. Independent risk factors for NS C glabrata were determined by stepwise logistic regression. Results. Of 1385 C glabrata cases, 83 (6.0%) had NS isolates (19 intermediate and 64 resistant); the proportion of NS isolates rose from 4.2% in 2008 to 7.8% in 2014 (P < .001). The proportion of NS isolates at each hospital ranged from 0% to 25.8%; 3 large, academic hospitals accounted for almost half of all NS isolates. In multivariate analysis, prior echinocandin exposure (adjusted odds ratio [aOR], 5.3; 95% CI, 2.6–1.2), previous candidemia episode (aOR, 2.5; 95% CI, 1.2–5.1), hospitalization in the last 90 days (aOR, 1.9; 95% CI, 1.0–3.5, and fluconazole resistance [aOR, 3.6; 95% CI, 2.0–6.4]) were significantly associated with NS C glabrata. Fifty-nine percent of NS C glabrata cases had no known prior echinocandin exposure. Conclusion. The proportion of NS C glabrata isolates rose significantly during 2008–2014, and NS C glabrata frequency differed across hospitals. In addition to acquired resistance resulting from prior drug exposure, occurrence of NS C glabrata without prior echinocandin exposure suggests possible transmission of resistant organisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Proportion of cases with Candida glabrata isolates that were nonsusceptible to echinocandins, by surveillance site and year, 2008–2014. Surveillance areas: Atlanta metropolitan area, Georgia ([GA] started in March 2008), Baltimore City and County, Maryland ([MD] started in June 2008), Tri-county region of Portland Oregon ([OR] started in January 2011), and Knoxville, Tennessee ([TN] started in January 2011); combined population is 7.9 million persons and includes 80 hospital sites.](https://figures.cochat.ai/paper-figures/99210950937c4263932f9e9540f30adf/epidemiology-and-risk-factors-for-echinocandin-nonsusceptible-candida-glabrata-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“as reported in a previous publication using EIP surveillance data, resistance tends to be concentrated in a few tertiary care hospitals that care for high-acuity patients with malignancies and transplants; three hospitals out of 80 included in the candidemia EIP surveillance accounted for more than half of all echinocandin-resistant isolates (19).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent reports indicate an increase in multidrug-resistant C. glabrata isolates in the United States (19,20).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [19]
In the citing paper
“Acquisition of resistance towards echinocandins is not as common as towards azoles, yet it is far from rare and is significantly linked with prior exposure to the drugs [46].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Self-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“For instance, because echinocandins are the recommended first-line treatment for candidemia in cancer patients with neutropenia [5], hospitals with higher numbers of neutropenic cancer patients are likely to”
BackgroundAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 3×
“quentially acquire and express unlinked resistance-conferring mutations [8].”
BackgroundResultResistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Pfaller, M. A., Andes, D. R., Diekema, D. J., Horn, D. L., Reboli, A. C., Rotstein, C., Franks, B., & Azie, N. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101510 · Cited by 396 · cited 4×
“Although this study is population-based surveillance, fi ndings from these surveillance areas may not be generalizable to the entire United States.”
BackgroundInfluentialPfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01901-07 · Cited by 387
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
Self-citationCleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366
Self-citationSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Cleveland, A. A., Harrison, L. H., Farley, M. M., Hollick, R., Stein, B., Chiller, T. M., Lockhart, S. R., & Park, B. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120452 · Cited by 304
Self-citationLockhart, S. R., Iqbal, N., Cleveland, A. A., Farley, M. M., Harrison, L. H., Bolden, C. B., Baughman, W., Stein, B., Hollick, R., Park, B. J., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01283-12 · Cited by 299
Self-citationAnsari, F. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg459 · Cited by 222
FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Beyda, N. D., John, J., Kilic, A., Alam, M. J., Lasco, T. M., & Garey, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu407 · Cited by 174
Shields, R. K., Nguyen, M. H., Press, E. G., Kwa, A. L., Cheng, S., Du, C., & Clancy, C. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00027-12 · Cited by 171
Drug-Resistant Candida glabrata Infection in Cancer Patients
Farmakiotis, D., Tarrand, J. J., & Kontoyiannis, D. P. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2011.140685 · Cited by 152
Rüttimann, S., Keck, B., Hartmeier, C., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380964 · Cited by 149
Zimbeck, A. J., Iqbal, N., Ahlquist, A. M., Farley, M. M., Harrison, L. H., Chiller, T., & Lockhart, S. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00836-10 · Cited by 136
Self-citationEvaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed
Valerio, M., Rodríguez-González, C. G., Munoz, P., Caliz, B., Sanjurjo‐Sáez, M., Bouza, E., on behalf of the COMIC Study Group (Collaborative Group on Mycoses), Anaya, F., Bañares, R., Bouza, E., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku053 · Cited by 136
Pfaller, M. A., Messer, S. A., Hollis, R. J., Boyken, L., Tendolkar, S., Kroeger, J., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00946-09 · Cited by 129
Fekkar, A., Dannaoui, É., Meyer, I., Imbert, S., Brossas, J., Uzunov, M., Mellon, G., Nguyen‐Quoc, S., Guiller, E., Caumes, É., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2096-9 · Cited by 76
Toxicity Mechanisms of Amphotericin B and Its Neutralization by Conjugation with Arabinogalactan
Kagan, S. A., Ickowicz, D. E., Shmuel, M., Altschuler, Y., Sionov, E., Pitusi, M., Weiss, A. M., Farber, S., Domb, A. J., & Polacheck, I. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00612-12 · Cited by 73
Pham, C. D., Bolden, C. B., Kuykendall, R. J., & Lockhart, S. R. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03378-13 · Cited by 51
Self-citationBlanchard, E., Lortholary, O., Boukris-Sitbon, K., Desnos-Ollivier, M., Dromer, F., Guillemot, D., & the French Mycosis Study Group (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00690-11 · Cited by 48
Is age a risk factor for Candida glabrata colonisation?
Malani, A. N., Psarros, G., Malani, P. N., & Kauffman, C. A. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01941.x · Cited by 23
Research works printed but not linked: 2
- CLSI, 2008, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Third Edition
- CLSI, 2012, M27-S4. Reference Method for Broth Dilution antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement
Cited by
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Infection in Organ Transplantation
Fishman, J. A. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14208 · Cited by 809
Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
Metadata
- Authors
- Vallabhaneni, S., Cleveland, A. A., Farley, M. M., Harrison, L. H., Schaffner, W., Beldavs, Z. G., Derado, G., Pham, C. D., Lockhart, S. R., & Smith, R. M.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Emory University (US)
- Johns Hopkins University (US)
- Vanderbilt University (US)
- Acute and Communicable Disease Prevention, Oregon Health Authority, Portland
- Corresponding author
- Vallabhaneni, Snigdha
- ORCID
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015
- Volume
- 2
- Issue
- 4
- Pages
- ofv163-ofv163
- ISSN
- 2328-8957 (ISSN-L)
- PMC
- PMC4677623
- OpenAlex
- W2276873560
- Cited by
- 187
- References
- 24
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 13 · 2023: 12 · 2022: 12 · 2021: 21 · 2020: 22 · 2019: 25 · 2018: 23 · 2017: 28 · 2016: 6
- FWCI
- 14.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Open Forum Infectious Diseases (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- Candida glabrata, candidemia, echinocandin resistance, antifungal susceptibility, risk factors, fluconazole resistance, bloodstream infection, emerging fungal infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.